What is the optimal dose of escitalopram for the treatment of obsessive-compulsive disorder? A naturalistic open-label study

被引:9
|
作者
Shim, Geumsook [1 ]
Park, Hye Youn [1 ]
Jang, Joon Hwan [1 ]
Kim, Euitae [1 ]
Park, Hye Yoon [1 ]
Hwang, Jae Yeon [1 ,2 ]
Kim, Sung Nyun [1 ]
Jang, Go-Eun [3 ]
Kwon, Jun Soo [1 ,2 ,3 ]
机构
[1] Seoul Natl Univ, Coll Med, Dept Psychiat, Seoul 110744, South Korea
[2] Seoul Natl Univ, Brain & Cognit Sci WCU Program, Coll Nat Sci, Seoul 110744, South Korea
[3] SNU MRC, Clin Cognit Neurosci Ctr, Neurosci Inst, Seoul, South Korea
关键词
escitalopram; high dose; obsessive-compulsive disorder; selective serotonin reuptake inhibitors; SEROTONIN REUPTAKE INHIBITORS; POSITRON-EMISSION-TOMOGRAPHY; SOCIAL ANXIETY DISORDER; DOUBLE-BLIND; PREFRONTAL CORTEX; 20; MG; PLACEBO; PHARMACOTHERAPY; DOPAMINE; TRANSPORTER;
D O I
10.1097/YIC.0b013e32834a5c09
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
This study explored the efficacy and tolerability of very high doses (maximum dose of >40 mg/day), high doses (maximum dose of 25-40 mg/day), and standard doses (maximum dose of <= 20 mg/day) of escitalopram (ESC) as an anti-obsessive-compulsive disorder treatment in a naturalistic clinical setting. We reviewed the medical records of all patients with obsessive-compulsive disorder (n = 246) who had taken ESC between May 2006 and September 2009, and assigned Clinical Global Impression (CGI) scores, retrospectively. Of the total sample, 24.4, 38.2, and 37.4% patients received very high, high, and standard doses of ESC, and the mean daily maximum doses of ESC were 57.3 +/- 12. mg, 33.9 +/- 5.4 mg, and 13.4 +/- 5.8 mg, respectively. The CGI-Severity scores in each group decreased significantly after treatment with ESC, as evidenced by response rates (i.e. CGI-Improvement scores of 1 or 2) of 46.3, 43.2, and 26.2%, respectively. Although some adverse events increased in a dose-dependent manner, most could be managed with an ESC dose adjustment. These results imply that doses less than or equal to 40 mg/day ESC are sufficient for symptomatic improvement with good tolerability for most patients. Very high doses of ESC, on the other hand, can be considered for patients with inadequate therapeutic responses to the administration of 40 mg/day ESC. Int Clin Psychopharmacol 26:284-290 (C) 2011 Wolters Kluwer Health | Lippincott Williams & Wilkins.
引用
收藏
页码:284 / 290
页数:7
相关论文
共 50 条
  • [31] An open-label trial of riluzole, a glutamate antagonist, in children with treatment-resistant obsessive-compulsive disorder
    Grant, Paul
    Lougee, Lorraine
    Hirschtritt, Matthew
    Swedo, Susan E.
    JOURNAL OF CHILD AND ADOLESCENT PSYCHOPHARMACOLOGY, 2007, 17 (06) : 761 - 767
  • [32] Topiramate augmentation in treatment-resistant obsessive-compulsive disorder: A retrospective, open-label case series
    Van Ameringen, M
    Mancini, C
    Patterson, B
    Bennett, M
    DEPRESSION AND ANXIETY, 2006, 23 (01) : 1 - 5
  • [33] Quetiapine addition to serotonin reuptake inhibitor treatment in patients with treatment-refractory obsessive-compulsive disorder: An open-label study
    Denys, D
    van Megen, H
    Westenberg, H
    JOURNAL OF CLINICAL PSYCHIATRY, 2002, 63 (08) : 700 - 703
  • [34] OPEN FIXED DOSE TRIAL OF FLUOXETINE IN THE TREATMENT OF OBSESSIVE-COMPULSIVE DISORDER
    KIM, SW
    DYSKEN, MW
    DRUG DEVELOPMENT RESEARCH, 1990, 19 (03) : 315 - 319
  • [35] Sarcosine Therapy for Obsessive Compulsive Disorder A Prospective, Open-Label Study
    Wu, Po-Lun
    Tang, Hwa-Sheng
    Lane, Hsien-Yuan
    Tsai, Chen-An
    Tsai, Guochuan E.
    JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY, 2011, 31 (03) : 369 - 374
  • [36] Escitalopram in the treatment of major depressive disorder: An open-label naturalistic trial in various settings
    Hranov, L.
    Staleva, I.
    JOURNAL OF AFFECTIVE DISORDERS, 2008, 107 : S92 - S93
  • [37] Escitalopram prevents relapse of obsessive-compulsive disorder
    Fineberg, Naomi A.
    Tonnoir, Brigitte
    Lemming, Ole
    Stein, Dan J.
    EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2007, 17 (6-7) : 430 - 439
  • [38] Obsessive-Compulsive Disorder: Strategies for Optimal Treatment
    Hollander, Eric
    Abramowitz, Jonathan S.
    Koran, Lorrin M.
    Pallanti, Stefano
    JOURNAL OF CLINICAL PSYCHIATRY, 2008, 69 (11) : 1750 - +
  • [39] Citalopram in the treatment of obsessive-compulsive disorder: an open pilot study
    Koponen, H
    Lepola, U
    Leinonen, E
    Jokinen, R
    Penttinen, J
    Turtonen, J
    ACTA PSYCHIATRICA SCANDINAVICA, 1997, 96 (05) : 343 - 346
  • [40] What is the optimal way to subdivide obsessive-compulsive disorder?
    de Mathis, Maria Alice
    Diniz, Juliana Belo
    do Rosario, Maria Conceicao
    Torres, Albina R.
    Hoexter, Marcelo
    Hasler, Gregor
    Miguel, Euripedes C.
    CNS SPECTRUMS, 2006, 11 (10) : 762 - +